Important note

This AI stock analysis for Tarsus Pharmaceuticals is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Tarsus Pharmaceuticals - AI Stock Analysis

Analysis generated July 21, 2024

Tarsus Pharmaceuticals is a biopharmaceutical company concentrated on the development and commercialization of therapeutic treatments in the field of eye care. The company is focused on innovative solutions and has shown a strong commitment to research and development, which is reflected in the significant growth rates seen in their financial reports. Their portfolio includes products that are in various stages of clinical trials, and they are continuously looking to expand their market reach and product line.

Fundamental Analysis

In the last quarter, Tarsus Pharmaceuticals reported a revenue of $28M. This figure represents a remarkable growth of 111.18% compared to the previous quarter, underscoring the company’s strong quarter-over-quarter performance. Furthermore, when compared to the same quarter last year, the revenue has surged by an astounding 1,004.56%, highlighting significant year-over-year growth.

The net income for the last quarter was $36M, which is an increase of 14.73% from the previous quarter. Although this quarter-over-quarter growth is encouraging, the picture isn't equally promising year-over-year, with a decline of 52.57% from the same quarter last year. This decrease may raise concerns regarding the sustainability of profitability.

Turning to EBITDA, the figure stands at $38M for the last quarter. This represents a quarter-over-quarter increase of 7.99%, yet a year-over-year decrease of 66.07%. This substantial year-over-year decline in EBITDA could be perceived as a red flag, requiring investors to consider the reasons behind this drop.

Technical Analysis

Currently, Tarsus Pharmaceutical’s stock price is $27.04. This price marks a 3.68% increase compared to a month ago, suggesting a positive short-term trend. In terms of long-term perspective, the stock has risen by 9.83% over the past year, which is a promising sign of steady progress.

Examining the technical indicators, the trend appears to be bearish as the current SMA10 is 28.06, lower than the previous SMA10 of 28.34. This could indicate a potential downtrend in price movement. Moreover, the RSI stands at 28.5, suggesting that the stock is potentially oversold and may soon experience a bullish reversal.

Alternative Data Analysis

Evaluating alternative data can provide additional insights into Tarsus Pharmaceuticals's performance. For customer acquisition, the company’s webpage received around 19,000 visitors, but this figure has dropped by 53% over the last couple of months, which could indicate a waning interest or a potential loss in customers.

Despite the declining web traffic, AltIndex’s AI score for Tarsus Pharmaceuticals is 68. The AI score incorporates various fundamental, technical, and alternative data signals and a score above 65 generally indicates a "buy" signal. This positive AI score can bolster investor confidence amid mixed fundamental data.

Conclusion and Recommendation

Tarsus Pharmaceuticals presents a mixed but generally positive outlook. The company's impressive revenue growth both quarter-over-quarter and year-over-year highlights its strong market positioning. However, the significant year-over-year declines in net income and EBITDA raise questions about profitability sustainability. The technical analysis suggests caution as the trend is bearish, despite positive short and long-term stock price increments. The oversold RSI condition hints at a potential bullish reversal.

Considering the alternative data, while the decrease in site visitors is worrisome, the overall positive AI score of 68 suggests a strong "buy" signal. Investors should weigh these factors and closely monitor upcoming financial reports and market conditions. As such, while the stock appears promising, it is recommended to proceed with cautious optimism and perhaps a diversified portfolio approach to mitigate risk.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.